Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II

Speciality: Oncology

Description:

A warm welcome to all the medical professionals joining us for this insightful and educational session on understanding the molecular differences between EGFR EXON 19 Deletion and EXON 21 L858R Mutations in non-small cell lung cancer (NSCLC).

These two mutations represent the most common and clinically significant alterations in the epidermal growth factor receptor (EGFR) gene, each playing a unique role in tumor biology and treatment response. The EXON 19 Deletion involves the removal of a specific portion of the gene, typically between codons 746 and 750, leading to constitutive activation of the EGFR tyrosine kinase domain. This alteration drives downstream signaling pathways such as PI3K/AKT and RAS/RAF/MEK, which are crucial for cancer cell proliferation, angiogenesis, and resistance to apoptosis.

In contrast, the EXON 21 L858R Mutation is characterized by a single-point substitution of leucine to arginine at codon 858. This mutation similarly enhances tyrosine kinase activity but differs in structural conformation and sensitivity to tyrosine kinase inhibitors (TKIs). As a result, while both mutations respond to EGFR-targeted therapies, subtle differences in drug efficacy, resistance mechanisms, and prognostic value have been observed in clinical practice.

Understanding these molecular variances is essential for implementing precision oncology in NSCLC, guiding decisions around first-line therapy, monitoring resistance, and improving patient outcomes. This session will offer clarity on the biochemical underpinnings of both mutations and their impact on therapeutic strategies.

So, listen to this comprehensive webinar, absorb the shared expertise, and stay tuned to Hidoc for more such engaging and informative medical discussions tailored for today’s oncology professionals.

See More Webinars @ Hidoc Webinars